AllDocs -> cancers

MANAGEMENT OF SUPERFICIAL BLADDER CANCER WITH THE COMBINATION OF INTRAVESICAL CHEMOTHERAPY AND HYPERTHERMIA www.Medical-Enterprises.com Medical Enterprises Europe B.V. Assumburg 152 B, 1081GC Amsterdam, The Netherlands Tel: +31 (0) 20 642 3719 Fax: +31 (0) 20 642 1161 E-mail: synergo-med@planet.nl MEL-Medical Enterprises Ltd. 6 Odem st. P.O.B 7166, Kiryat Matalon Petah-Tikva, 49170, Israel Tel: +972 3 924 4830 Fax: +972 3 924 5340 E-mail: mel@mel.co.il Page 2 2 LIST OF PUBLICATIONS - (1991 - 2004) 1. Van der Heijden A.G, Cornelius F. J. J, Verhaegh G, O’Donnell M.A, Schalken J.A, Witjes J.A. The Effect of Hyperthermia on Mitomycin-C Induced Cytotoxicity in Four Human Bladder Cancer Cell Lines. Submitted for publication to J Urol 2004. 2. Van der Heijden A.G, Kiemeney L.A, Gofrit O.N, ...

LifePro Financial Services Inc. 225 West Plaza – Solana Beach, CA 92075 – PH: 888-543-3776 – FAX: 858-793-4981 – Email: greg@lifepro.net Cancer – Bladder LifePro Finacial Services, Inc. – Phone: 888-543-3776 – FAX: 858-793-4981 – email: greg@lifepro.net Proposed Insured Name: M F Date of Birth or Age Face Amount: __ Max. Premium; $__/yr. UL WL Term Survivorship Do you currently smoke cigarettes? Y N If no, did you ever smoke: Never Quit (Date): Do you currently use any other tobacco products (i.e. nicotine patches, cigars, pipe, chew): Y N If yes, please provide details: When did you last use any form of tobacco:__(Month) __(Year) Type used last: (1) Date or age of diagnosis: (2) Date of last treatment: (3) What type of treatment was performed? Surgery Radiation Chemotherapy (2) How often does the proposed insured visit their physician for follow-up? Monthly Every 3 ...

426 Clinical Urology International Braz J Urol Official Journal of the Brazilian Society of Urology Vol. 28 (5): 426-436, September - October, 2002 TREATMENT OF PATIENTS WITH SUPERFICIAL BLADDER CANCER STRATIFIED BY RISK GROUPS TREATED WITH LYOPHILIZED MOREAU-RIO DE JANEIRO BCG STRAIN FRANCISCO P. FONSECA, WILSON BACHEGA JR, STÊNIO C. ZEQUI, ÁLVARO S. SARKIS, GUSTAVO GUIMARAES, ANTONIO V. M. PRIANTE, ADEMAR LOPES Section of Urology, Department of Pelvic Surgery, Cancer Hospital, São Paulo, SP, Brazil ABSTRACT Introduction: The Moreau-Rio de Janeiro BCG strain is considered the most effective to stimulate immunologic activity in mice. The objective of this prospective study was to evaluate BCG results for patients with superficial bladder cancer stratified by risk groups. Material and Methods: From April 1988 to May 2000, 100 patients were treated by transure- ...

RALPH W. WHITE, MD Professor and Chair Department of Urology ESCHELLE STAPP, MD Resident, Department of Urology University of California, Davis Sacramento, California B ladder cancer is the most com- mon malignancy encountered by urologists. It is estimated that, in 1998, 54,400 cases of bladder cancer will be diagnosed in the United States, leading to approximately 12,500 More than 90% of bladder tumors are transitional cell carcinomas. Risk factors for the development transitional cell carcinoma include cigarette smoking and exposure to arylamines (such as aniline dyes), certain drugs, and pelvic Cigarette smoking is the cause of 25% to 60% of all bladder cancers, and smokers have two times the risk of developing this cancer than do Fortunately, most patients (80%) with newly diagnosed ...

Incidence and Mortality Rate Trends While urinary bladder cancer incidence is significantly higher in Whites than in African Americans, the mortality rates are nearly the same, due in large part to the later stage at diagnosis among African Americans. Rates for Hispanics, Asians and Pacific Islanders, and American Indians/Alaskan Natives are lower than those for Whites or African Americans. Overall incidence has stayed the same or risen slightly since the 1980s, but mortality dropped through the 1980s, resulting in increased survival. Males have greater incidence and mortality rates than women in all ethnic groups. It is estimated that approximately $1.9 billion* is spent in the United States each year on treatment of bladder cancer . *In 1996 dollars, as determined by Brown, Riley, Schussler, and Etzioni and reported in the National Cancer Institute’s ...

Chapter II.8 II.8-1 Cost of Bladder Cancer C HAPTER II.8. C OST OF B LADDER C ANCER Clicking on the sections below will take you to the relevant text. II.8.A Background II.8.A.1 Description II.8.A.2 Concurrent Effects II.8.A.3 Causality & Special Susceptibilities II.8.A.4 Treatments and Services II.8.A.5 Prognosis II.8.B Costs of Treatments and Services II.8.B.1 Methodology II.8.B.2 Results of Medical Cost Analysis II.8.B.3 Other Studies II.8.C Uncertainties and Limitations II.8.C.1 Uncertainties Surrounding Key Inputs to the Analysis II.8.C.2 Scope of the Analysis Page 2 Chapter II.8 II.8-2 Cost of ...

Urinary Bladder Cancer 102 CANCER INCIDENCE AND MORTALITY IN NEW MEXICO, 1970-1996 Major Epidemiologic Features Urinary bladder is the only anatomic site in this monograph for which incidence statistics are based on both invasive and non-invasive (in-situ) cases. This is a widespread and customary practice employed to alleviate difficulty and error in interpreting varying language used by pathologists to describe the extent of anatomic invasion of bladder cancer . Bladder cancer is the most common cancer of the urinary tract. It accounts for about 4 to 5% of all annually diagnosed cancers in the U.S. and about 2% of all yearly cancer deaths. Overall mortality from bladder cancer is relatively low compared to incidence, reflecting the inclusion of non-invasive cases in the incidence data. The incidence of bladder cancer in the U.S. increased by about 10% ...

0 20 40 60 80 100 Relative Survival % Zero Two Four Six Eight Ten Twelve Years of Survival After Diagnosis In Situ All Remote Regional Local Local 40% In Situ 42.2% Regional 10.5% Remote 5.6% Unknown 1.5% 1998 Stage at Diagnosis Percent of Total State of New Mexico Urinary Bladder Cancer Survival Rates 1973-1998 265 Total Cases

I Survived Bladder Cancer By Vincent E. Sussman http://survivorofcancer.homestead.com/ Sunday, October 3, 1999 Today, it is a beautiful day. I just returned from my two-mile walk and feel refreshed and fairly calm. Tomorrow, I check into St. Raphael Hospital in New Haven, Connecticut. On Tuesday, October 5, I will undergo a serious operation to remove my bladder and replace it with an exterior plastic bag. Two months ago, when I was going out to play golf, I noticed my urine was wine colored. It appeared to be blood. My golf game was worse than usual. When I returned home, I mentioned the blood in my urine to my wife, Rhoda. She was quite upset and told me to call my doctor immediately. The earliest appointment I could schedule with my urologist was several days later. I was told to bring a sample of urine to the lab for testing. The tests were negative for infection. Although my urologist, Dr. ...

INTRODUCTION The process of cancer progression consists of multisteps, which can be rate limiting since a failure or an in- sufficiency at any of the steps aborts the process (1-3). The outcome of the process is dependent on both the intrinsic properties of the tumor cells and the re- sponses of the host. The steps or events required for the formation of tumor invasion and metastasis are the same in all tumors (Fig. 1). The major steps in tumor progression are as follows : 1) After the ini- tial transformation, tumor cells grow at the primary site. 2) Neovascularization must occur when the tumor mass forms 2 mm more in diameter (4). Several angiogenic factors play key roles to establish neovascularization (5-7). 3) Local invasion of the basement membrane and degradation of the stroma are necessary for migration from the primary site (8 -11). Matrix metalloproteinases ...

A Meta-Analysis of Case-Control Studies of Bladder Cancer in Coffee Drinkers M. S. LACHS, C. M. VISCOLI, R. I. HORWITZ Yale University School of Medicine SUMMARY A preliminary meta-analysis of case-control studies investigating the risk of bladder cancer in coffee drinkers was performed. Three investigators developed core criteria for studies to be included in the meta-analysis that included appropriate selection of cases and controls, ascertainment of exposure disease sequence, and adjustment for the confounding effects of smoking. Significant methodological heterogeneity was noted, and eight of 32 identified studies adhered to all these criteria and were included in the meta-analysis. Coffee drinkers were not found to be at substantially increased risk of lower urinary tract cancer , and this finding persisted at the highest levels of coffee exposure.

Survival of Cancer Patients in Northern Ireland 1993-96 53 Incidence and Mortality In 1996, cancer of the bladder was the fifth most common cancer in men and the twelfth most common cancer in women, accounting for over 4% and 2% of all cancers registered respectively. Between 1993 and 1996, an average of 157 men and 70 women were registered each year as having bladder cancer , with the incidence of bladder cancer in women rising in this period. Women had a statistically significant upward trend (P<0.05) in their incidence EASR, corresponding to an increase of 1.2 cases per 100,000 per year. There was no statistically significant (P>0.05) trend in the incidence EASR for men (Figure 12.1). Between 1993 and 1996, approximately 63 men and 30 women died annually from bladder cancer . There were no statistically significant (P>0.05) trends in the mortality EASRs for men ...

Combined radiotherapy and chemotherapy in muscle invasive bladder cancer RADIOTHERAPY PLANNING FORM Please attach this form to the Radiotherapy plan for identification purposes. PATIENT DETAILS Hospital Name _ Patient initials Trial Number RADIOTHERAPY PLANNING DETAILS Planned treatment: Standard Volume Radiotherapy Reduced Volume Radiotherapy Date treatment began Which of the following methods were used to plan this patient’s radiotherapy? Method 1 – Two Phase Technique Method 2 - IMRT/Concomitant Boost Plan – One Phase Technique What type of planning was used? Conformal planning Conventional planning Is a copy of the Radiotherapy plan attached? Yes No Signature _ Date form completed dd mm yyyy

Phase 1 Clerkship Seminar: Hematuria/ Bladder Cancer Submitted by Dr. Michael Jewett Learning Objectives 1. To learn what constitutes clinically significant hematuria and how to determine the cause. 2. To understand the causes and prevention, how to diagnose and how to treat bladder cancer . Cases 1. A 50 year old woman presents to her family physician for a routine examination. She is otherwise well and asymptomatic urologically. The subsequently reported urinalysis is 2+ for blood • As her family physician, how would you proceed? The repeat is unchanged and microscopic examination reveals 7 rbc/hpf. • As his family physician, how would you proceed? 2. A 65 year old man presents to his family physician with a 1 week history of hematuria. He describes painless red coloration throughout each urination that he assumes is blood. He is otherwise ...

30 Fast Facts – Urology Highlights 2001– 02 30 TJ Christmas and ME Laniado Charing Cross Hospital and The Royal Marsden Hospitals; and The Royal Free Hospital, London, UK Bladder cancer Diagnosis. Two new promising tests for bladder cancer have emerged. Survivin is an inhibitor of apoptosis that is selectively over-expressed in common human cancers, including bladder cancer . The detection of survivin in urine had a sensitivity of 100% and a specificity of 95% for bladder cancer in a group that included patients with haematuria and urinary tract infection. 1 The survivin assay detected both low- and high-grade carcinoma in situ and therefore might be sufficiently reliable to rule out a cystoscopy. Hyaluronic acid (HA) and its degrading enzyme hyaluronidase (HAase) are intricately associated with bladder cancer angiogenesis and ...

Bladder Cancer Stage IV Stage III Stage II Stage I T1- Tumor invades the subepithelial connective tissue T2- Tumor invades muscle T2a- Tumor invades the superficial muscle T2b- Tumor invades deep muscle T3- Tumor invades perivesical tissue T3a- Microscopically T3b- Macroscopically T4- Tumor invades prostate, uterus, vagina, pelvic wall, or abdominal wall T4a- Tumor invades the prostate, uterus, or vagina T4b- Tumor invades the pelvic wall, abdominal wall N0- No regional lymph node metastasis N1- Metastasis to single lympn node, 2cm or less in size N2- Metastasis to single lymph node 2-5 cm in size, or multiple lymph nodes, none greater than 5 cm N3- Metastasis to a single lymph node >5cm in size M0- No distant metastasis M1- Distant metastasis T1,N0,M0 T2a,N0,M0 T2b,N0,M0 T3a,N0,M0 T3b,N0,M0 T4a,N0,M0 T4b,N0,M0 Any T,N1,M0 ...

Bladder Cancer History Physical Exam Workup Hematuria Plank pain Lower extremity swelling Weight loss Abdominal pain Bone pain Abdominal mass Inguinal lymphadenopathy Cystoscopy with brushings and biopsy Urine cytology CXR Excretory urography Bone scan in muscle invave cancers CT abd/pelvis Bladder Cancer Copyright 1998 - 2002 © Vesta, Inc. www.flash-med.com

bladder cancer 513-681C Homework 1 Due: April 23, 2002 A case-control study of bladder cancer was conducted to test its putative association with dietary consumption of substance E. Cases and non-cases were selected randomly from white male hospital patients between 50 and 60 years of age residing in a large metropolitan area. The table below summarizes the data by history of cigarette smoking. From previous investigations, it is known that smoking is a risk factor for bladder cancer . Note that consumption of substance E has been dichotomized into consumers (E) and non-consumers (). SMOKERS NON-SMOKERS E E ...

Cancer Program information at www.cedars-sinai.edu/ cancer Call 310-423-2440 or 1-800-CEDARS-1 [1-800-233-2771] for information Cancer -specific Support and Information Page 1 of 6 Cancer Program: Cancer -Specific Support and Information Services The following groups provide information and support related to specific types of cancer . Most services are free of charge. • Bladder Cancer American Foundation for Urologic Disease, Inc. 1128 N. Charles St. Baltimore, MD 21201-2463 Telephone: 410-468-1800 Fax: 410-469-1800 • Breast Cancer Encore Plus Sponsored by the YWCA and provides exercise and support programs Telephone: 202-628-3636 Fax: 202-783-7123 In the Los Angeles area: Greater Los Angeles.213-365-2991 Glendale .818-242-4155 Fullerton .714-871-4488 San Pedro..310-547-0831 Reach ...

bladder cancer SRR data A B C D E F G H I J K L M N O P Q R S T U 1 Department of Health 2 Compendium of Clinical and Health Indicators 2000 3 Source: Office for National Statistics ...

research for a cure laboratory without walls National Foundation for Cancer Research Cancer FAQs about bladder cancer Frequently Asked Questions about common cancers. Page 2 Cancer FAQs What are the different types of bladder cancer ? There are three main types of bladder tumors, each differentiated by the way the cancerous cells appear under a microscope. By far the most common form is urothelial carcinoma (also known as transitional cell carcinoma , or TCC ), which accounts for approximately 90 percent of all bladder cancer cases. There are several subtypes of urothelial carcinoma, including noninvasive forms (in which the cancer is limited to the innermost layer of the bladder , called the urothelium) and invasive forms (in which the cancer has spread from the urothelium into ...

375 Early detection of bladder cancer in hematuria patients: Vision becomes reality P. Oehr , University Bonn, Germany. Conclusions The superior sensitivity of NMP22-BladderChek® over cytology, at the specificity of 98%, and the negative predictive value of 98%, give reason to call it an easy to handle cancer screening assay. Combined use with cytology can result in a highly reliable screening: under the condition "both test are positive", no false positive results arose, making this assumption a 100% tumor inclusion criterion in 67% of the patients who had developed a yet undetected urinary bladder cancer . In addition, a negative predictive value of 98% for NMP22-BladderChek® is an excellent exclusion criterion. Independently, NMP22-BladderChek® can detect 82% to 86% urinary bladder ...

bladder cancer Combined radiotherapy and chemotherapy in muscle invasive bladder cancer RANDOMISATION CHECKLIST HOSPITAL DETAILS Hospital__ Consultant in charge __Person randomising Pt __ Referring Urologist _ Referring Hospital __ Yes No Do not proceed until consent obtained & checklist are completed Do not proceed until consent obtained & checklist are completed WRITTEN CONSENT OBTAINED? HAS THE Eligibility CHECKLIST BEEN COMPLETED? PATIENT?S DETAILS Patient?s name Patient?s Initials Gender Male ...

BLADDER CANCER - All Sections BLADDER CANCER What Is Cancer ? Cancer develops when cells in a part of the body begin to grow out of control. Although there are many kinds of cancer , they all start because of out-of-control growth of abnormal cells. Normal body cells grow, divide, and die in an orderly fashion. During the early years of a person's life, normal cells divide more rapidly until the person becomes an adult. After that, cells in most parts of the body divide only to replace worn-out or dying cells and to repair injuries. Because cancer cells continue to grow and divide, they are different from normal cells. Instead of dying, they outlive normal cells and continue to form new abnormal cells. Cancer cells often travel to other parts of the body where they begin to grow and replace normal tissue. This process, called metastasis, occurs as the cancer cells ...

Bladder Cancer Overview: About 55,000 individuals are diagnosed with bladder cancer in the United States each year and about 10,000 deaths are reported for the condition. Bladder cancer is most common among individuals over age 50; the condition is three times more common in men than in women. Smoking has been indicated as a major risk factor, as is exposure to chemicals in certain industrial applications. The disease is also common with frequent visitors to the tropics where the parasitic infec- tion with schistosomiasis is prevalent. The most common type of bladder cancer is transitional cell carcinoma, representing roughly 90% of all bladder cancers. These cancers arise from the epithelial cells that line the bladder . Other types of bladder cancer include papillary, squamous cell carcinoma, and adenocarcinoma, which have a poorer diagnosis and are rated higher. Bladder ...

70 16 Cancer of the bladder Summary When compared with other cancer sites, relative survival after diagnosis of bladder cancer is good. During the 1992–1997 period, one-year relative survival after diagnosis with bladder cancer was 86.9% for males and 78.2% for females and five-year relative survival after diagnosis was 70.8% for males and 64.7% for females (Table 16.1). Survival ten years after diagnosis was 65.8% for males and 62.0% for females in 1987–1991, the most recent period for which ten-year relative survival data are available (Figure 16.2; Tables 16.2 and 16.3). Between 1982–1986 and 1992–1997, there were no statistically significant changes in relative survival after diagnosis of bladder cancer for males or females (Figure 16.2; Tables 16.2 and 16.3). As age at diagnosis increased, five-year relative survival decreased. Five-year relative survival ...

bladder cancer YLL data A B C D E F G H I J K L M 1 Department of Health 2 Compendium of Clinical and Health Indicators 2000 3 Source: Office for National Statistics 4 March 2001 ...